Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 1
2009 1
2011 2
2012 1
2013 1
2016 4
2017 2
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. Maertens O, et al. Among authors: lauchle jo. Cancer Res. 2017 Nov 1;77(21):5706-5711. doi: 10.1158/0008-5472.CAN-17-1789. Epub 2017 Oct 9. Cancer Res. 2017. PMID: 28993414 Free PMC article. Review.
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Chang T, et al. Among authors: lauchle jo. J Clin Invest. 2016 Jan;126(1):404. doi: 10.1172/JCI85325. Epub 2016 Jan 4. J Clin Invest. 2016. PMID: 26727232 Free PMC article. No abstract available.
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Rauen KA, et al. Among authors: lauchle jo. Am J Med Genet C Semin Med Genet. 2011 May 15;157C(2):136-46. doi: 10.1002/ajmg.c.30294. Epub 2011 Apr 14. Am J Med Genet C Semin Med Genet. 2011. PMID: 21495172 Free PMC article.
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. Lyubynska N, et al. Among authors: lauchle jo. Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069. Sci Transl Med. 2011. PMID: 21451123 Free PMC article.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Italiano A, et al. Among authors: lauchle jo. Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076. Ann Oncol. 2018. PMID: 29788155 Free article. Clinical Trial.
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K. Lauchle JO, et al. Nature. 2009 Sep 17;461(7262):411-4. doi: 10.1038/nature08279. Epub 2009 Sep 2. Nature. 2009. PMID: 19727076 Free PMC article.
14 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page